Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year Extension of OraSure Technologies Agreement and a New Manufacturing Facility


24.04.2017

  • Longstanding relationship between companies fortified by multi-year contract extension
  • Grifols is currently building an $80 million manufacturing facility that will optimize production and expand capacity

Emeryville, CA, April  24, 2017 – Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, announces that it has restated its 2005 agreement with OraSure Technologies ("OraSure"), a leader in point-of-care diagnostic tests.

Under terms of the agreement, Grifols, a worldwide provider of recombinant antigens for HCV, HIV, and HBV diagnostic tests, supplies antigens for OraSure's OraQuick HCV Rapid Antibody Test. The test is FDA approved for qualitatively detecting hepatitis C virus antibodies in whole blood obtained through the use of a fingerstick or venipuncture. It enables healthcare providers to deliver results in 20 minutes from individuals 15 years of age and older.

"OraSure is committed to delivering high-quality infectious disease diagnostic products for our customers. As one of our trusted suppliers, Grifols' focus on service, quality and collaboration play a key role in our ongoing relationship," said Douglas A. Michels, President and CEO of OraSure Technologies.

OraSure's decision to extend its agreement reaffirms Grifols' value as an experienced and reliable supplier of high-quality diagnostic antigens. It highlights Grifols' ongoing commitment to build long-term relationships with diagnostic partners, and to develop, manufacture and supply these materials to support the improvement of innovative diagnostic assays.

"OraSure is a valued customer that shares our commitment to developing breakthrough diagnostic solutions to ensure the safest, most effective care for patients," said Vice President and General Manager of Grifols Diagnostic Solutions, Ramon Biosca. "We are very excited to continue this important relationship."

As part of Grifols' investment for future growth and to meet a global demand, the company is currently building an $80 million, state-of-the-art, biological manufacturing facility in the San Francisco Bay Area. Grifols is in the process of validating the facility and preparing to file a license with the US Food and Drug Administration certifying proper design, monitoring, and control of manufacturing processes and facilities. The facility will provide long-term, high-quality commercial manufacturing for a developing product selection of diagnostic antigens, including proteins expressed in E. coli, yeast and mammalian cells.

"Grifols' expanded manufacturing capabilities will allow us to continue to meet the demand for our growing portfolio of specialized diagnostics reagents. With strong partnerships, such as the one we share with OraSure, and our commitment to invest in our Diagnostic Division, we are well positioned to further strengthen our abilities to provide effective, high- quality antigens to a global community," said Biosca. The new Grifols manufacturing facility is expected to be completed in 2018.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.

For more information on OraSure Technologies, please visit www.orasure.com